There has been an increase in the use of synthetic marijuana, which has resulted in severe adverse events and increased emergency room department visits. The following geographic areas are particularly affected and require special attention: Long Island, Brooklyn, Upper Manhattan and Syracuse. OMH is also aware of individual cases in other areas of the state. Please distribute the information below to staff in all mental health programs including clinics, other outpatient programs, and residential programs.
Clinical Advisory Mixed use, larger scale congregate housing is an important and viable form of community living. However, there are times when the numbers of individuals with serious mental illness residing in certain types of housing result in housing experiences that are not clinically appropriate to the needs of such persons.
OMH Releases Guidance Memo on the Use of PRN Medications The Office of Mental Health recently released guidance for all hospitals under its jurisdiction, on the use of PRN medications. It is intended to replace all previous guidance and policy on this topic, including OMH Official Policy PC-530, "PRN for Agitation." It is effective immediately.
OMH Letter to Families on the Use of Antidepressants in Children and Adolescents In 2004, the U.S. Food and Drug Administration (FDA) announced a warning and precautions to strengthen safeguards for children and adolescents because of an increased risk of suicidality in those treated with antidepressant mediations. In response to subsequent news reports, OMH developed a letter that could be used with parents and families to explain the FDA warning that now has been extended to young adults aged 24 or less. In light of the continuing need for information in this area, the original OMH letter has been revised.